ASTRO/SNMMI Joint Session: Unlocking Success in Radiopharmaceutical Therapy: Collaboration between Radiation Oncology, Nuclear Medicine and Industry

Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer. Novel RPTs are in development for every major cancer type, and the market projects that RPT will expand significantly. For example, PSMA-targeting RPT therapy has generated over $1 billion in revenue within just two years of being on the market. Despite this rapid growth, there has not been a corresponding surge in interest among our society members in delivering or developing these therapies. This activity shares insights from providers who have successfully established and managed RPT programs in both academic and community settings, spanning the fields of Radiation Oncology and Nuclear Medicine. Panelists discuss their experiences, including successes, challenges and common pitfalls to avoid. The panel features both community and academic Radiation Oncologists from ASTRO, as well as Nuclear Medicine Physicians representing SNMMI.

Topics:

  1. Application of PRO's to Clinical Trials
    Deborah W. Bruner, PhD, RN, FAAN
  2.  

This activity is available from December 1, 2025, through 11:59 p.m. Eastern time on November 30, 2027. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, physicists, diagnostic radiologists, radiation therapists, dosimetrists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop an understanding of what is needed in the clinic space for safe and compliant RPT delivery.
  • Explain the current practice of modern RPTs and understand the framework for clinical implementation.
  • Develop an understanding of the importance of patient selection and monitoring with molecular imaging. 


 

 

 

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
12/01/2025
Course expires: 
11/30/2027
Cost:
$149.00
Rating: 
0
  • Erin F. Gillespie, MD, MPH, is employed by University of California, San Diego. Dr. Gillespie serves an uncompensated role as Co-founder of eContour.  
  •  

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until November 30, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.